MRNA
Price
$106.56
Change
-$4.03 (-3.64%)
Updated
Mar 28, 6:59 PM EST
34 days until earnings call
PFE
Price
$27.74
Change
-$0.03 (-0.11%)
Updated
Mar 28, 6:59 PM EST
33 days until earnings call
Ad is loading...

Compare predictions MRNA vs PFE

Header iconMRNA vs PFE Comparison
Open Charts MRNA vs PFEBanner chart's image
Moderna
Price$106.56
Change-$4.03 (-3.64%)
Volume$2.25M
CapitalizationN/A
Pfizer
Price$27.74
Change-$0.03 (-0.11%)
Volume$14.01M
CapitalizationN/A
View a ticker or compare two or three
MRNA vs PFE Comparison Chart

Loading...

MRNADaily Signal changed days agoGain/Loss if shorted
 
Show more...
PFEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
MRNA vs. PFE commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a Hold and PFE is a Buy.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (MRNA: $106.56 vs. PFE: $27.75)
Brand notoriety: MRNA and PFE are both notable
MRNA represents the Biotechnology, while PFE is part of the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: MRNA: 100% vs. PFE: 91%
Market capitalization -- MRNA: $40.8B vs. PFE: $157.14B
MRNA [@Biotechnology] is valued at $40.8B. PFE’s [@Pharmaceuticals: Major] market capitalization is $157.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $570.99B to $0. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B. The average market capitalization across the [@Pharmaceuticals: Major] industry is $87.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRNA’s FA Score shows that 1 FA rating(s) are green whilePFE’s FA Score has 2 green FA rating(s).

  • MRNA’s FA Score: 1 green, 4 red.
  • PFE’s FA Score: 2 green, 3 red.
According to our system of comparison, PFE is a better buy in the long-term than MRNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRNA’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 6 bullish TA indicator(s).

  • MRNA’s TA Score: 6 bullish, 4 bearish.
  • PFE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MRNA is a better buy in the short-term than PFE.

Price Growth

MRNA (@Biotechnology) experienced а +2.37% price change this week, while PFE (@Pharmaceuticals: Major) price change was +0.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.98%. For the same industry, the average monthly price growth was +8.91%, and the average quarterly price growth was +90.55%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.67%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was -2.01%.

Reported Earning Dates

MRNA is expected to report earnings on May 02, 2024.

PFE is expected to report earnings on May 01, 2024.

Industries' Descriptions

@Biotechnology (+4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Major (+0.67% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
A.I.dvisor published
a Summary for MRNA with price predictions.
OPEN
A.I.dvisor published
a Summary for PFE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
PFE($157B) has a higher market cap than MRNA($40.8B). PFE has higher P/E ratio than MRNA: PFE (75.00) vs MRNA (26.46). MRNA YTD gains are higher at: 7.149 vs. PFE (-2.162). PFE has higher annual earnings (EBITDA): 9.56B vs. MRNA (-3.28B). PFE has more cash in the bank: 12.7B vs. MRNA (8.6B). MRNA has less debt than PFE: MRNA (1.24B) vs PFE (70.8B). PFE has higher revenues than MRNA: PFE (58.5B) vs MRNA (6.75B).
MRNAPFEMRNA / PFE
Capitalization40.8B157B26%
EBITDA-3.28B9.56B-34%
Gain YTD7.149-2.162-331%
P/E Ratio26.4675.0035%
Revenue6.75B58.5B12%
Total Cash8.6B12.7B68%
Total Debt1.24B70.8B2%
FUNDAMENTALS RATINGS
PFE: Fundamental Ratings
PFE
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
88
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MRNAPFE
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
60%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
50%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
72%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 1 day ago
59%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
58%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
51%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 2 days ago
55%
Declines
ODDS (%)
Bearish Trend 15 days ago
83%
Bearish Trend 7 days ago
63%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
59%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
54%
View a ticker or compare two or three
Ad is loading...
MRNADaily Signal changed days agoGain/Loss if shorted
 
Show more...
PFEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DSP10.650.43
+4.21%
Viant Technology
ZYME10.500.20
+1.94%
Zymeworks
BGNE156.351.27
+0.82%
BeiGene Ltd
OLK23.51-0.09
-0.38%
Olink Holding AB (publ)
TPHS0.15-0.01
-4.34%
Trinity Place Holdings